Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Vanda M. Stepanek"'
Autor:
Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock
Publikováno v:
Cell Reports, Vol 6, Iss 2, Pp 377-387 (2014)
Despite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abno
Externí odkaz:
https://doaj.org/article/121a3483acb24454b24b119984535acb
Autor:
Razelle Kurzrock, Robert A. Wolff, E. Scott Kopetz, Michael J. Overman, Rajyalakshmi Luthra, J. Jack Lee, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha-Paul, Jennifer J. Wheler, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Filip Janku, Prasanth Ganesan
PDF file - 66K, Target-matched therapy in patients with pik3ca mutations (n=17).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0854571d20e31b3f0f52581da7860676
https://doi.org/10.1158/1535-7163.22498105.v1
https://doi.org/10.1158/1535-7163.22498105.v1
Autor:
Razelle Kurzrock, Robert A. Wolff, E. Scott Kopetz, Michael J. Overman, Rajyalakshmi Luthra, J. Jack Lee, Vanda M. Stepanek, Siqing Fu, Sarina A. Piha-Paul, Jennifer J. Wheler, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Filip Janku, Prasanth Ganesan
Target-matched treatment with PI3K/AKT/mTOR pathway inhibitors in patients with diverse advanced cancers with PIK3CA mutations have shown promise. Tumors from patients with colorectal cancer were analyzed for PIK3CA, KRAS, and BRAF mutations. PIK3CA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72beb079560c7bbd907003c9f34cf1e0
https://doi.org/10.1158/1535-7163.c.6535792.v1
https://doi.org/10.1158/1535-7163.c.6535792.v1
Autor:
Razelle Kurzrock, Apostolia M. Tsimberidou, Rajyalakshmi Luthra, J. Jack Lee, Sarina A. Piha-Paul, Siqing Fu, Vanda M. Stepanek, David S. Hong, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Filip Janku
PDF file - 70K, Co-existing PIK3CA and KRAS mutations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f7a1365f6a73408adbcb99252a9269
https://doi.org/10.1158/0008-5472.22396493.v1
https://doi.org/10.1158/0008-5472.22396493.v1
Autor:
Razelle Kurzrock, Apostolia M. Tsimberidou, Rajyalakshmi Luthra, J. Jack Lee, Sarina A. Piha-Paul, Siqing Fu, Vanda M. Stepanek, David S. Hong, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Filip Janku
PIK3CA mutations may predict response to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype has not been investigated. Patients with diverse cancers referred to the Clinical Center for Targeted Therapy w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18937576d16bd6dce19ec6db2882fd8f
https://doi.org/10.1158/0008-5472.c.6504587
https://doi.org/10.1158/0008-5472.c.6504587
Autor:
Jennifer Thurmond, Manisha H. Shah, Vanda M. Stepanek, Mitch A. Phelps, Ming Poi, Jennifer Sexton, Lai Wei, Larry J. Schaaf, Sigurdis Haraldsdottir, Filip Janku, Erin M. Bertino, Amir Mortazavi, Vivianne Velez-Bravo, Cynthia Timmers, Kari Kendra, Vivek Subbiah, Susan Geyer
Publikováno v:
JCO Precision Oncology. :1-19
Purpose Several tumor types carry BRAF mutations and vascular endothelial growth factor pathway upregulation. Resistance mechanisms to BRAF inhibitors can include platelet-derived growth factor-β upregulation. Dabrafenib, a BRAF inhibitor, and pazop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f907d9255d4c703c7c9fab8e5cde407a
https://doi.org/10.1200/po.17.00247
https://doi.org/10.1200/po.17.00247
Autor:
Karena Kosco, Filip Janku, Lorieta Leppin, Patrick P. Lin, Razelle Kurzrock, Latifa Hassaine, Jason C. Poole, Cecile Rose T. Vibat, Mark Erlander, Funda Meric-Bernstam, Vanda M. Stepanek, Veronica R. Holley, Goran Cabrilo
Publikováno v:
Oncotarget
Oncotarget, vol 5, iss 11
Oncotarget, vol 5, iss 11
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8651ec88ad797a3f4d3c08dd55d3b22a
https://doi.org/10.18632/oncotarget.1964
https://doi.org/10.18632/oncotarget.1964
Autor:
Aung Naing, Jennifer J. Wheler, Filip Janku, Rajyalakshmi Luthra, J. Jack Lee, Razelle Kurzrock, Russell Broaddus, Siqing Fu, Apostolia Maria Tsimberidou, Ralph Zinner, David S. Hong, Vanda M. Stepanek, Gerald S. Falchook, Sarina Anne Piha-Paul, Stacy L. Moulder
Publikováno v:
Cell Reports, Vol 6, Iss 2, Pp 377-387 (2014)
SummaryDespite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39bbcdf9633f9558db521d334c56a717
https://doi.org/10.1016/j.celrep.2013.12.035
https://doi.org/10.1016/j.celrep.2013.12.035
Autor:
Aung Naing, Filip Janku, J. Jack Lee, Vanda M. Stepanek, Siqing Fu, Gerald S. Falchook, Prasanth Ganesan, Sarina Anne Piha-Paul, Razelle Kurzrock, Rajyalakshmi Luthra, Apostolia Maria Tsimberidou, E. Scott Kopetz, Michael J. Overman, Robert A. Wolff, David S. Hong, Jennifer J. Wheler
Publikováno v:
Molecular Cancer Therapeutics. 12:2857-2863
Target-matched treatment with PI3K/AKT/mTOR pathway inhibitors in patients with diverse advanced cancers with PIK3CA mutations have shown promise. Tumors from patients with colorectal cancer were analyzed for PIK3CA, KRAS, and BRAF mutations. PIK3CA-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10dff1643f8aa0631484dfc84544fe9a
https://doi.org/10.1158/1535-7163.mct-13-0319-t
https://doi.org/10.1158/1535-7163.mct-13-0319-t
Autor:
Rebecca Richards-Kortum, Michelle D. Williams, Vanda M. Stepanek, Darren Roblyer, Timothy J. Muldoon, Ann M. Gillenwater
Publikováno v:
Head & Neck
Background The purpose of this study was to evaluate the ability of high-resolution microendoscopy to image and quantify changes in cellular and architectural features seen in early oral neoplasia in vivo. Methods A high-resolution microendoscope (HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b77f89ccf1eeb917038f5ee63b68c411
http://europepmc.org/articles/PMC3078517
http://europepmc.org/articles/PMC3078517